Subgroup analysis of predictive factors for PFS and OS demonstrated that the clinical benefit of this regimen was not related with sex, age, treatment program, primary tumor site, KRAS status, MPV, NLR, LDH and D-Dimer. The gene discussed is KRAS; the disease is neoplasm.